Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 12
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03742258	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	completed	Phase 1	12	Northwestern UniversityOTHER	1	Jun 18, 2025	clinicaltrials
NCT02112526	Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma	completed	Phase 1	21	Acerta Pharma BVINDUSTRY	2	Dec 20, 2024	clinicaltrials